LEP and schizophrenia: Furthermore, our findings support strong correlations between inflammation and high levels of leptin and IR in schizophrenic patients, which may partially explain the higher risk of metabolic disorders in CS patients comorbid with IR, and reducing chronic inflammation in the body in clinical practice may be a therapeutic target to prevent or treat comorbid metabolic disorders in schizophrenia.